These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

704 related articles for article (PubMed ID: 25252180)

  • 1. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-occurring adverse events enable early prediction of progression-free survival in metastatic renal cell carcinoma patients treated with sunitinib: a hypothesis-generating study.
    Kucharz J; Dumnicka P; Kuzniewski M; Kusnierz-Cabala B; Herman RM; Krzemieniecki K
    Tumori; 2015; 101(5):555-9. PubMed ID: 26045121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with renal insufficiency.
    Kim KH; Kim HY; Kim HR; Sun JM; Lim HY; Lee HJ; Lee S; Bae WK; Rha SY; ;
    Eur J Cancer; 2014 Mar; 50(4):746-52. PubMed ID: 24332573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients.
    Donskov F; Michaelson MD; Puzanov I; Davis MP; Bjarnason GA; Motzer RJ; Goldstein D; Lin X; Cohen DP; Wiltshire R; Rini BI
    Br J Cancer; 2015 Dec; 113(11):1571-80. PubMed ID: 26492223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced/metastatic renal cell carcinoma?
    Goldstein D; Rosenberg JE; Figlin RA; Townsend RR; McCann L; Carpenter C; Pandite L
    Eur J Cancer; 2016 Jan; 53():96-104. PubMed ID: 26702763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma.
    Escudier B; Roigas J; Gillessen S; Harmenberg U; Srinivas S; Mulder SF; Fountzilas G; Peschel C; Flodgren P; Maneval EC; Chen I; Vogelzang NJ
    J Clin Oncol; 2009 Sep; 27(25):4068-75. PubMed ID: 19652072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study.
    Noize P; Grelaud A; Bay JO; Chevreau C; Gross-Goupil M; Culine S; Ferrière JM; Moulin F; Robinson P; Balestra A; Lamarque S; Bernard MA; Lassalle R; Rouyer M; Droz-Perroteau C; Moore N; Fourrier-Réglat A; Ravaud A
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1561-1569. PubMed ID: 28573786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-target Toxicities Predictive of Survival in Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: A Multicenter Retrospective Study.
    Bolzacchini E; Pinotti G; Bertù L; Verusio C; Galli L; Mumoli N; Barbara C; Danova M; Bregni M; Artale S; Rossini C; Nigro O; Antonuzzo A; Derosa L; Torchio M; Barzaghi S; Ricci I; Suter M; Ballerio A; Vallini I; Dentali F
    Clin Genitourin Cancer; 2020 Apr; 18(2):e145-e156. PubMed ID: 31889670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors.
    Livne-Segev D; Gottfried M; Maimon N; Peer A; Neumann A; Hayat H; Kovel S; Sella A; Mermershtain W; Rouvinov K; Boursi B; Weitzen R; Berger R; Keizman D
    Isr Med Assoc J; 2014 Jun; 16(6):347-51. PubMed ID: 25058995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin Inhibitors as Treatment of Sunitinib/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.
    Penttilä P; Rautiola J; Poussa T; Peltola K; Bono P
    Clin Genitourin Cancer; 2017 Jun; 15(3):384-390.e3. PubMed ID: 28089721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension as a predictive factor for survival outcomes in patients with metastatic renal cell carcinoma treated with sunitinib after progression on cytokines.
    Szmit S; Langiewicz P; Złnierek J; Nurzyński P; Zaborowska M; Filipiak KJ; Opolski G; Szczylik C
    Kidney Blood Press Res; 2012; 35(1):18-25. PubMed ID: 21849795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A; Hercbergs AH; Hanovich E; Kovel S
    Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma.
    Nagyiványi K; Budai B; Bíró K; Gyergyay F; Noszek L; Küronya Z; Németh H; Nagy P; Géczi L
    Clin Genitourin Cancer; 2016 Aug; 14(4):314-22. PubMed ID: 26774206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.